Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not
hand-edited; a correction means re-running the fetch against a newer release.
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
01–1011–100101–1,0001,001–10,000over 10,000not in the reporting set
Cases of Measles reported to WHO by national authorities, latest year 2025. Reported cases undercount true infections, and a zero can mean elimination or simply that nobody reported — each country page carries a data-quality grade saying which. This is occurrence as reported, not a modelled distribution.
What it does
7
disease-burden figures
2
post-infectious sequelae figures
9
effectiveness estimates
5
vaccine adverse-event figures
4
pooled or expert review
5
surveillance, ecological, modelling
Case-fatality projection for 2016 to 2030
1.3 CFR (%)
all age groups in the included LMIC studies, low-income and middle-income countries per case
quote
The mean projected case-fatality ratio in 2016-2030 was 1·3% (0·4-3·7).
Portnoy A 2019 Lancet Glob Health
Lowest and highest vaccine effectiveness reported:74%(Di Pietrantonj C 2021 Cochrane Database Syst Rev; Measles after a known exposure, children exposed to measles) to 96%(Di Pietrantonj C 2021 Cochrane Database Syst Rev; Measles cases, children up to 15 years). Two of 4 estimates, each from its own study; not a summary figure.
Pooled or expert review
Vaccine effectiveness against any disease or infection 4
What can follow the illness
Recurrent fever episodes after past measles infection
1.80 OR for fever in previous 2 weeks
children aged 9 to 59 months, Democratic Republic of the Congo; vs children with no history of measles
quote
RESULTS: The odds of fever in the previous 2 weeks were 1.80 (95% confidence interval [CI], 1.25-2.60) among children for whom measles was reported compared to children with no history of measles.
Ashbaugh HR 2019 J Pediatric Infect Dis Soc
When problems appear: after the infection, and after the vaccine
Two separate clocks on the same logarithmic scale. The first starts at the infection and shows when its sequelae are described as beginning; the second starts at the dose and shows when the vaccine's adverse events are described as beginning. Each bar is one source's printed window, not a synthesis; hover for the source.
After the infection: post-infectious syndromes 1After vaccination: adverse events 5
Clinical description: when it is observed to begin
Compensation-table interval
Study risk window: when events were counted, not typical onset
Each figure is the one its source printed, with the sentence it came from. Nothing is recomputed, averaged or converted.
Burden
Measure
As the source states it
Source
Annual Deaths
95 000global · 2024
quote
An estimated 95 000 people died from measles in 2024 - mostly children under the age of five years, despite the availability of a safe and cost-effective vaccine.
Not searched yet. No US-approved antiviral for this virus was found in the openFDA drug label endpoint. Only US labels were searched, and only drugs the FDA classes as antivirals.
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are
on the label and in national guidelines. This page does not give medical advice and does not
render dosing. A development stage is not a measure of how well something works.
Cite this page. Measles virus. Vaccine Data Navigator, Open Source Medicine Foundation. Built 9 November 2026 from the ICTV Virus Metadata Resource (MSL41) and NCBI Taxonomy/GenBank. https://vaccinedatanavigator.org/virus-navigator/viruses/measles-virus.html